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Summary
Background Increased concentrations of eosinophils in blood and sputum in chronic obstructive pulmonary disease 
(COPD) have been associated with increased frequency of exacerbations, reduced lung function, and corticosteroid 
responsiveness. We aimed to assess whether high eosinophil concentrations in either sputum or blood are associated 
with a severe COPD phenotype, including greater exacerbation frequency, and whether blood eosinophils are 
predictive of sputum eosinophils.
Methods We did a multicentre observational study analysing comprehensive baseline data from SPIROMICS in 
patients with COPD aged 40–80 years who had a smoking history of at least 20 pack-years, recruited from six clinical 
sites and additional subsites in the USA between Nov 12, 2010, and April 21, 2015. Inclusion criteria for this analysis 
were SPIROMICS baseline visit data with complete blood cell counts and, in a subset, acceptable sputum counts. We 
stratified patients on the basis of blood and sputum eosinophil concentrations and compared their demographic 
characteristics, as well as results from questionnaires, clinical assessments, and quantitative CT (QCT). We also 
analysed whether blood eosinophil concentrations reliably predicted sputum eosinophil concentrations. This study is 
registered with ClinicalTrials.gov (NCT01969344).
Findings Of the 2737 patients recruited to SPIROMICS, 2499 patients were smokers and had available blood counts, 
and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cells per μL) and 1237 with high 
(≥200 cells per μL) blood eosinophil counts. 827 patients were eligible for stratification by mean sputum eosinophil 
percentage: 656 with low (<1·25%) and 171 with high (≥1·25%) sputum eosinophil percentages. The high sputum 
eosinophil group had significantly lower median FEV1 percentage predicted than the low sputum eosinophil group 
both before (65·7% [IQR 51·8–81·3] vs 75·7% [59·3–90·2], p<0·0001) and after (77·3% [63·1–88·5] vs 82·9% 
[67·8–95·9], p=0·001) bronchodilation. QCT density measures for emphysema and air trapping were significantly 
higher in the high sputum eosinophil group than the low sputum eosinophil group. Exacerbations requiring 
corticosteroids treatment were more common in the high versus low sputum eosinophil group (p=0·002). FEV1 
percentage predicted was significantly different between low and high blood eosinophil groups, but differences were 
less than those observed between the sputum groups. The high blood eosinophil group had slightly increased airway 
wall thickness (0·02 mm difference, p=0·032), higher St George Respiratory Questionnaire symptom scores 
(p=0·037), and increased wheezing (p=0·018), but no evidence of an association with COPD exacerbations (p=0·35) 
or the other indices of COPD severity, such as emphysema measured by CT density, COPD assessment test scores, 
Body-mass index, airflow Obstruction, Dyspnea, and Exercise index, or Global Initiative for Chronic Obstructive Lung 
Disease stage. Blood eosinophil counts showed a weak but significant association with sputum eosinophil counts 
(receiver operating characteristic area under the curve of 0·64, p<0·0001), but with a high false-discovery rate of 72%.
Interpretation In a large, well characterised cohort of former and current smoking patients with a broad range of COPD 
severity, high concentrations of sputum eosinophils were a better biomarker than high concentrations of blood eosinophils 
to identify a patient subgroup with more severe disease, more frequent exacerbations, and increased emphysema by QCT. 
Blood eosinophils alone were not a reliable biomarker for COPD severity or exacerbations, or for sputum eosinophils. 
Clinical trials targeting eosinophilic inflammation in COPD should consider assessing sputum eosinophils. 
Funding National Institutes of Health, and National Heart, Lung, and Blood Institute.
Introduction
Airway inflammation in chronic obstructive pulmonary 
disease (COPD) is characterised by increased concen­
trations of neutrophils,1 macrophages,2 proteases, 
interleukin 6 and 8, and T­helper­1 (Th1) cytokines,3 
whereas airway inflammation in asthma is characterised 
by increased concentrations of eosinophils and Th2 
cytokines.4 However, some research has challenged these 
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presumed differences between the characteristic markers 
of asthma and COPD.
The ECLIPSE study1 reported that in COPD, sputum 
neutrophil concentrations were weakly associated with 
lung function and health status, but not associated with 
exacerbations, emphysema, or systemic inflammation. 
ECLIPSE reported a mean 1·3% (SD 2·6) sputum 
eosinophil concentration in 359 patients with COPD,1 but 
did not observe associations of blood eosinophils with 
radiological measures of emphysema or with COPD 
exacerbations and hospital admissions. ECLIPSE reported 
that concentrations of persistently 2% or more blood 
eosinophils (150 cells per μL) were associated with 
evidence of higher FEV1, lower St George Respiratory 
Questionnaire (SGRQ) score, and modified M edical 
Research Council score compared with intermittent 
concentrations or concentrations persistently less than 
2%.5 Other COPD studies have reported that increased 
eosinophils in both blood and sputum are associated with 
respiratory exacerbations and greater hyperinflation when 
assessed by quantitative CT (QCT),6,7 suggesting that Th2 
inflammation m ight c ontribute t o C OPD p rogression. 
Furthermore, increased epithelial Th2 signature gene 
expression has been associated with more severe airflow 
obstruction in two COPD cohorts.8 Eosinophils might 
therefore be a potential biomarker in COPD because 
eosinophilia is related to corticosteroid responsiveness.1,9–11 
In a phase 2 clinical trial, anti­interleukin­5 receptor 
therapy reduced the occurrence of COPD exacerbations in 
a subgroup of patients with high concentrations of blood 
and sputum eosinophils.12
Establishing disease severity in patients with COPD 
is complex and involves more than lung function 
assessments; additional clinical characteristics have 
been incorporated in successive revisions of the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
severity stages.13 The current classification includes 
lung function, symptom scores, and exacerbation 
frequency. Thus, the severity of COPD is dependent on 
multiple characteristics, and eosinophilic inflammation 
might contribute.
Previous reports suggest that blood eosinophil counts 
might be a useful surrogate measure of airway 
eosinophils in COPD,11,14 although blood eosinophils 
appear to correlate poorly with sputum eosinophils in 
asthma,15,16 and do not distinguish between populations 
who are asthma dominant, COPD dominant, or those 
who have asthma–COPD overlap.17 However, larger 
studies of comprehensively phenotyped patients with 
COPD often do not have robust sputum eosinophil data 
either because sputum induction was not done or 
sputum induction cohorts were small.18–21 Thus, whether 
or not peripheral eosinophils do accurately predict airway 
eosinophils is unknown.
We investigated the hypotheses that high concentrations 
of blood and sputum eosinophils in patients with a history 
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Research in context
Evidence before this study
We did a PubMed search for original research reports using the 
search terms “eosinophils”, “sputum”, “blood”, and “COPD” from 
April 15, 2014, to May 18, 2017, which yielded 154 articles, of 
which 32 were reviews. No publication date or language 
restrictions were used. Addition of “severity” as a search term 
reduced the publication number to 33 (seven reviews) and 
addition of “exacerbation” reduced the number to 35 
(one review). However, many of these reports have further 
limitations. Some did not have sputum or blood eosinophil data 
for comparison, did not specifically focus on the severity of 
chronic obstructive pulmonary disease (COPD; eg, exacerbations), 
or were based on small numbers of patients (<100 per group), 
which limits the power to make conclusions for broader COPD 
populations. Generally, eosinophils in COPD have been linked to 
more frequent exacerbations and responsiveness to 
corticosteroid therapy, suggesting more severe disease. Often, 
studies are done primarily in populations that have met selection 
criteria for clinical trials, including the presence of COPD 
exacerbations. Thus, comparison of blood and sputum eosinophil 
concentrations for an association with severity of COPD 
phenotype has not been well studied in a general smoking 
population with a broad range of COPD severity, nor has possible 
substitution of blood eosinophils as a biomarker for sputum 
eosinophils in COPD populations been carefully examined.
Added value of this study
This study shows that in a large, comprehensively characterised 
smoking cohort with a broad range of COPD severity, increased 
sputum eosinophils, but not blood eosinophils alone, had 
significant associations with multiple measures of COPD 
severity, including exacerbations, increased emphysema and air 
trapping, St George Respiratory Questionnaire scores, and 
Global Initiative for Chronic Obstructive Lung Disease 
spirometric stage. Blood eosinophils showed weak association 
with sputum eosinophils and as a single biomarker had few 
significant associations with COPD severity and exacerbations. 
However, this study does show that increased blood eosinophils 
in combination with increased sputum eosinophils show 
associations with COPD exacerbations and severity.
Implications of all the available evidence
Increased sputum eosinophils in patients with a broad range of 
COPD severities identify patients who are more likely to have 
severe disease and exacerbations. Blood eosinophils as a single 
biomarker do not accurately predict sputum eosinophils, and 
do not show any association with disease severity or 
exacerbations unless observed in combination with increased 
sputum eosinophils. The findings from this study will be 
important in the design of therapeutic trials that target 
eosinophilic inflammation in COPD.
of tobacco use are associated with a more severe COPD 
phenotype, identified by diminished lung function, QCT 
measurements of emphysema or air­trapping, clinical 
COPD characteristics, and exacerbations. We also 
investigated relationships between blood and sputum 
eosinophils to establish whether blood eosinophil 
concentrations reliably predicted sputum eosinophil 
concentrations. Measuring blood eosinophils is an easier 
and less expensive option than sputum induction in a 
clinical setting. Thus, an ability to predict sputum 
eosinophils accurately from blood eosinophil 
concentrations would be useful for clinical studies and 
patient care. These hypotheses were assessed in the 
comprehensively characterised SPIROMICS cohort.22 A 
portion of these studies were presented as an abstract at 
the 2016 American Thoracic Society meeting.23
Methods
Study design and patients
We did a multicentre observational study of baseline data 
of the Subpopulations and Intermediate Outcome 
Measures in COPD Study (SPIROMICS) cohort.
Individuals aged 40–80 years with current or former 
history of tobacco use (≥20 pack­years) were enrolled in 
SPIROMICS at six clinical sites and additional subsites in 
the USA.22 2737 patients were recruited to the SPIROMICS 
cohort between Nov 12, 2010, and April 21, 2015. Inclusion 
criteria for this analysis were SPIROMICS baseline visit 
data with complete blood cell counts and, in a subset, 
acceptable sputum counts. The cohort included specific 
groups of smokers with preserved lung function (31%), 
GOLD stages 1 and 2 (41%), or GOLD stages 3 and 4 (21%), 
and a control group of non­smokers (7%). COPD was 
defined in long­term smokers as a post­bronchodilator 
FEV1:forced vital capacity (FVC) ratio of less than 0·7. All 
SPIROMICS participants had extensive baseline 
phenotypic characterisation as follows: lung function 
assessment before and after bronchodilation with 
salbutamol and ipratropium; CT total lung capacity (TLC) 
and residual volume measurements using QCT indicators 
for emphysema (% voxels less than –950 Hounsfield Units 
[HU]) at TLC and air trapping (% voxels less than –856 HU) 
at residual volume; airway metrics (VIDA Diagnostics, 
Coralville, IA, USA)24 and parametric response mapping 
(PRM) for functional small airways disease;25 collection of 
blood (for DNA, RNA, plasma, sera, IgE, and complete 
blood cell counts), urine (for cotinine and nicotine 
metabolites, proline­glycine­proline, and others as 
requested), 6­min walk distance, GOLD stage, Body­mass 
index, airflow Obstruction, Dyspnea, and Exercise (BODE) 
index, COPD assessment test (CAT) score, SGRQ, and 
medical history questionnaires; and records of numbers of 
exacerbations (from previous year), hospital admissions, 
respiratory exposures to vapours, gases, or fumes, and 
medications.22 Sputum was induced in a subset of the 
SPIROMICS patients, which was based on those who were 
capable of sputum induction and produced a sufficient 
sample (appendix p 23). Individuals with a primary asthma 
diagnosis were excluded, but all participants were asked if 
they had ever had a health­care professional say that they 
had asthma (previous asthma label). Information on the 
selection of stratification cutoffs, reproducibility, and other 
details are provided in the appendix (pp 2–5).
In the SPIROMICS study, patients with post­
bronchodilator FEV1 percentage predicted of 35% or more 
were eligible for sputum induction with saline solutions, 
and nebulised for three 7­min intervals each. Expectorated 
sputum samples were processed (appendix pp 3–4) and 
cytospin slides were read by the central reading centre at 
University of North Carolina (Chapel Hill, NC, USA). 
Other exclusion criteria were total leucocyte count of 100 or 
less, or more than 80% squamous epithelial cells. Patients 
Figure 1: Patient flow diagram
All never-smokers were excluded. Reasons for the reduced number of sputum slide 
samples available for analysis were as follows: no sputum produced upon 
completion of induction; no sputum processing form entered; removal of aliquots 
for mucus analysis and microbiome before processing leaving too little remaining 
sample for cytospin slide preparation; slides not sent to central slide-reading 
centre; and slide counts that were deemed unacceptable (leucocyte cell count <100 
or >80% squamous epithelial cells). 16 patients with acceptable sputum 
differential counts but without blood counts were added to those with both 
acceptable sputum counts and blood counts to form the sputum cohort.
190 patients excluded from sputum cohort
        179 patients with total leucocyte
                 count <100
          11 patients with >80% squamous
                epithelial cells
1498 patients excluded from sputum cohort
            947 patients who did not have
sputum collected
            551 patients with unavailable
sputum slides (no leucocyte count)
16 patients with unavailable blood counts
      but acceptable sputum slides
222 patients excluded
        199 non-smokers
           23 with unavailable blood counts
2737 patients recruited
2499 patients in the blood count cohort
1001 patients with available sputum slides
827 patients in the sputum cohort
   811 patients with acceptable sputum
            slides and blood counts
with no sputum collected or no slides prepared were also 
excluded from sputum analyses.
All SPIROMICS sites that enrolled patients obtained 
informed consent from patients and were approved by 
their institutional review boards.
Statistical analysis
Measures not meeting the Kolmogorov­Smirnov test for 
normal distribution were transformed by log, or square 
root values. Continuous variables were tested by 
parametric or non­parametric tests (appendix p 5; SAS 
 
version 9.2 and Sigmastat version 12.5). We analysed 
categorical variables with χ² or Fisher’s exact tests. 
Correlations were examined by Pearson correlation 
coefficient or linear regression. Receiver operating 
characteristic (ROC) analysis was done for blood 
eosinophil prediction of sputum eosinophils. We 
examined the false discovery rate, which was the number 
of false positives divided by false positives plus true 
positives. We did a classification tree analysis of sputum 
and blood eosinophils to model exacerbations using 
Rpart routines in R software package. p values of less 
Blood eosinophils <200 
cells per μL (n=1262)
Blood eosinophils 
≥200 cells per μL 
(n=1237)





Age, years 65 (56–70) 65 (59–71) 0·001 65 (57–71) 64 (57–71) 0·87
Sex <0·0001 0·99
Male 631 (50%) 730 (59%) ·· 377 (57%) 99 (58%) ··
Female 631 (50%) 507 (41%) ·· 279 (43%) 72 (42%) ··
Race <0·0001 0·90
White 934 (74%) 1004 (81%) ·· 511 (78%) 132 (77%) ··
Black 285 (23%) 173 (14%) ·· 110 (17%) 29 (17%) ··
Other 43 (3%) 60 (5%) ·· 35 (5%) 10 (6%) ··
Body-mass index 26·8 (23·7–30·9) 28·2 (24·5–32·1) <0·0001 28·3 (24·5–32·2) 28·1 (25·2–31·7) 0·92
Smoking pack-years 41 (30–60) 45 (34–60) 0·008 43 (32–60) 44 (33–60) 0·70
Cigarettes per day 15 (9–20) 15 (8–20) 0·97 15 (10–20) 15 (6–20) 0·52
Current smoker 522 (42%) 451 (37%) 0·003 293 (45%) 70 (41%) 0·39
Inhaled corticosteroids 404 (32%) 470 (38%) 0·002 169 (26%) 66 (39%) 0·002
IgE, IU/mL 34 (14–93) 49 (19–166) <0·0001 41 (16–104) 56 (15–203) 0·32
Sputum eosinophils, % 0·23 (0·00–0·76) 0·65 (0·12–2·42) <0·0001 ·· ·· ··
Blood eosinophils, cells per 
μL
·· ·· ·· 150 (100–200) 230 (160–350) <0·0001
Previous asthma 249 (20%) 255 (21%) 0·48 122 (19%) 48 (29%) 0·003
Childhood asthma 97 (8%) 118 (10%) 0·10 52 (8%) 20 (12%) 0·07
Data are median (IQR) or n (%). *Mann-Whitney rank sum test for continuous variables, χ² for categorical variables.
Table 1: Demographics for patients stratified by mean blood or sputum eosinophils
Blood eosinophils 
<200 cells per μL 
(n=1262)
 Blood eosinophils 
≥200 cells per μL 
(n=1237)





Lung function before bronchodilator
FEV1, L 1·86 (1·22–2·54) 1·81 (1·16–2·55) 0·38 2·15 (1·57–2·77) 1·83 (1·38–2·32) <0·0001
FEV1 percentage predicted 70·5 (46·6–88·2) 66·3 (42·0–85·6) 0·006 75·7 (59·3–90·2) 65·7 (51·8–81·3) <0·0001
FVC percentage predicted 87·2 (74·1–99·3) 84·4 (70·1–96·7) 0·0002 90·9 (78·9–100·0) 87·1 (76·9–97·1) 0·06
FEV1:FVC 0·64 (0·49–0·73) 0·61 (0·47–0·72) 0·016 0·66 (0·58–0·74) 0·61 (0·52–0·69) <0·0001
Lung function after bronchodilator
FEV1, L 2·05 (1·43–2·72) 2·03 (1·39–2·75) 0·62 2·34 (1·78–2·59) 2·11 (1·69–2·59) 0·003
FEV1 percentage predicted 77·7 (53·9–94·4) 74·2 (51·6–91·4) 0·008 82·9 (67·8–95·9) 77·3 (63·1–88·5) 0·001
FVC percentage predicted 92·9 (81·3–103·8) 90·5 (78·8–101·6) 0·001 94·5 (85·1–105·2) 94·2 (85·9–104·1) 0·84
FEV1:FVC 0·66 (0·50–0·76) 0·63 (0·49–0·74) 0·004 0·68 (0·59–0·76) 0·64 (0·55–0·72) 0·0002
Percentage FEV1 reversibility 9·3 (4·2–17·7) 9·8 (4·5–19·0) 0·46 8·0 (3·7–15·4) 11·6 (6·0–21·8) <0·0001
Data are median (IQR). FVC=forced vital capacity. *Mann-Whitney rank sum test for continuous variables.
Table 2: Lung function for patients stratified by mean blood or sputum eosinophils
than 0·05 were considered significant.26 An observational 
studies monitoring board meets annually to review the 
study and make recommendations to the National Heart, 
Lung, and Blood Institute. The SPIROMICS study is 
registered with ClinicalTrials.gov (NCT01969344).
Role of the funding source
The funder had no role in the study design, data 
collection, analysis, interpretation, or writing of this 
report.  The corresponding author had full access to all 
data in the study and all coauthors gave final approval for 
the decision to submit for publication.
Results
Of the 2737 patients recruited to SPIROMICS, 
2499 patients were smokers and had available blood 
counts (figure 1). Mean blood eosinophil count in these 
2499 patients was 200 cells per μL (SD 240; median 
190 cells per μL [IQR 100–250]; range 0–8300 cells per μL), 
thus, 200 cells per μL was used as the cutoff for analyses. 
A higher eosinophil cutoff of 300 cells per μL was also 
examined. The 2499 patients were grouped according to 
their blood eosinophil count: 1262 patients with low 
(<200 cells per μL) and 1237 with high (≥200 cells per μL) 
blood eosinophil counts.
Sputum slides were available for 1001 patients (figure 1). 
179 patients with differential counts (500–600 total cells) of 
100 leucocytes or less in total and 11 patients with 80% or 
more squamous epithelia were excluded from the analysis. 
In the 811 individuals with sputum counts, plus 16 other 
SPIROMICS patients who had sputum counts but not 
blood eosinophil counts available (total 827), the mean 
sputum eosinophil percentage was 1·25% (SD 4·25%; 
median 0·3% [IQR 0·00–0·97]; range 0–75%), so 1·25% 
was used as the cutoff for analyses. A higher cutoff of 2% 
for sputum eosinophils was also examined. The 827 patients 
with available sputum counts were grouped according to 
sputum eosinophil concentrations: 656 with low (<1·25%) 
and 171 with high (≥1·25%) sputum eosinophil counts.
We compared demographic characteristics between 
patients with high versus low mean blood eosinophil 
counts and between patients with high versus low mean 
sputum eosinophil percentages (table 1). Patients with 
low blood eosinophils (<200 cells per μL) differed 
significantly with regard to age, sex, race, body­mass 
index (BMI), smoking history (pack­years), the proportion 
who were current smokers, and the proportion who used 
inhaled corticosteroids from the patients with high blood 
eosinophil counts (≥200 cells per μL), although 
differences between the groups were small at less 
than 10%. Although the proportion of current smokers 
was smaller in the high eosinophil group, the number of 
cigarettes smoked each day was similar. Proportions of 
patients taking five different medications were not 
significantly different (appendix p 10). Total serum IgE 
concentrations and percentage sputum eosinophils were 
significantly higher in the high blood eosinophil group 
than the low blood eosinophil group, but no significant 
difference was recorded in the proportions of patients 
with a previous asthma label or childhood asthma 
(table 1). The median sputum eosinophil percentage in 
both groups was lower than the overall sputum 
eosinophil mean of 1·25%.
No significant difference was recorded between patients 
with low sputum eosinophil counts (<1·25%) and patients 
with high sputum eosinophils (≥1·25%) in terms of age, 
sex, race, BMI, smoking history (pack­years), cigarettes 
smoked per day, or the proportion who were current 
smokers. Lymphocyte counts were significantly different 
between the high and low sputum eosinophil groups 
(appendix p 11). The high sputum eosinophil group had a 
significantly greater proportion of patients who had used 
Blood eosinophils 
<200 cells per μL 
(n=1262)
Blood eosinophils 
≥200 cells per μL 
(n=1237)





TLC left upper lobe, 
percentage <–950 HU
3·22 (1·11 to 1·84) 3·77 (1·20 to 1·50) 0·66 2·24 (0·89 to 5·74) 2·88 (1·09 to 7·65) 0·046
TLC right upper lobe, 
percentage <–950 HU
2·78 (0·72 to 12·97) 2·87 (0·73 to 11·96) 0·76 1·73 (0·59 to 5·58) 2·43 (0·91 to 7·24) 0·011
TLC left lower lobe, 
percentage <–950 HU
2·09 (0·81 to 7·09) 2·42 (0·88 to 7·50) 0·23 1·60 (0·72 to 3·78) 1·98 (0·76 to 5·32) 0·044
Residual volume both lungs, 
percentage <–856 HU
17·4 (6·71 to 39·38) 18·91 (7·39 to 40·71) 0·28 12·52 (5·34 to 25·27) 17·20 (8·57 to 33·13) 0·001
PRM for functional small 
airways disease, %
14 (4 to 33) 15 (4 to 34) 0·21 9 (3 to 22) 13 (6 to 26) 0·011
Wall thickness of apical 
right upper lobe, mm
1·26 (1·15 to 1·37) 1·28 (1·16 to 1·39) 0·032 1·28 (1·18 to 1·38) 1·29 (1·19 to 1·42) 0·08
Taper ratio of apical 
right upper lobe
0·04 (–0·01 to 0·09) 0·04 (–0·01 to 0·09) 0·87 0·03 (–0·01 to 0·08) 0·03 (–0·01 to 0·08) 0·93
Data are median (IQR). TLC=total lung capacity. HU=Hounsfield units. PRM=parametric response mapping. *Mann-Whitney rank sum test for continuous variables.
Table 3: Imaging parameters for patients stratified by mean blood or sputum eosinophils
inhaled corticosteroids (table 1) and inhaled or nebulised 
bronchodilators than the low sputum eosinophil group 
(appendix p 10). The sputum eosinophil groups, unlike 
the blood eosinophil groups, did not have significantly 
different I gE c oncentrations. R egardless, t he I gE 
concentrations in the low and high sputum eosinophil 
groups were similar to those in the low and high blood 
eosinophil groups. The high sputum eosinophil group 
had a higher concentration of blood eosinophils than the 
low sputum eosinophil group (median 230 cells per μL 
[IQR 160–350] vs 150 cells per μL [100–200], p<0·0001) 
and a greater proportion of patients reporting a previous 
asthma label (48 [29%] vs 122 [19%], p=0·003). Similar 
results for blood or sputum eosinophil stratification were 
obtained with the higher cutoffs of 300 cells per mL blood 
eosinophils or 2% sputum eosinophils (appendix p 12).
Lung function assessments showed that the high blood 
eosinophil group had lower pre­bronchodilator FEV1 
percentage predicted than the low blood eosinophil group 
(median 66·3% [IQR 42·0–85·6] vs 70·5% [46·6–88·2], 
p=0·006; table 2), and a significant d ifference in  po st­
bronchodilator values was seen (74·2% [51·6–91·4] vs 77·7 
[53·9–94·4], p=0·008; table 2). The high sputum 
eosinophil group had significantly lower FEV1 percentage 
predicted versus the low sputum eosinophil group both 
before (65·7% [51·8–81·3] vs 75·7% [59·3–90·2], 
p<0·0001) and after (77·3% [63·1–88·5] vs 82·9% 
[67·8–95·9], p=0·001) broncho dilation. Because of the 
safety exclusion of patients with post­bronchodilator FEV1 
percentage predicted less than 35% from sputum 
induction, fewer patients with GOLD stages 3 and 4 were 
included in the sputum cohort than in the blood cohort. 
However, the difference between FEV1 percentage 
predicted before and after bronchodilation was greater 
between the sputum eosinophil groups than between the 
blood eosinophil groups. A significant difference was 
recorded in reversibility of baseline FEV1 percentage 
predicted between the high and the low sputum 
eosinophil groups (11·6 [6·0–21·7] vs 8 [3·7–15·4], 
p<0·0001), but no significant difference was observed 
between the blood eosinophil groups (p=0·46). Similar 
observations were noted between subgroups stratified by 
the 300 cells per μL blood eosinophil and 2% sputum 
eosinophil cutoffs (appendix p 13).
Blood eosinophils 
<200 per μL (n=1262)
Blood eosinophils 
≥200 per μL (n=1237)





GOLD stage 0·10† 0·001†
0 505 (40%) 425 (34%) 295 (45%) 51 (30%)
1 150 (12%) 153 (12%) 106 (16%) 31 (18%)
2 323 (26%) 359 (29%) 200 (31%) 76 (44%)
3 190 (15%) 200 (16%) 47 (7%) 11 (6%)
4 79 (6%) 86 (7%) 0 (0%) 1 (1%)
6-min walk distance, m 418 (354–482) 410 (341–471) 0·12 426 (372–482) 426 (363–478) 0·40
BODE index 1 (0–2) 1 (0–2) 0·29 0 (0–1) 1 (0–2) 0·09
COPD score (CAT) 13 (7–20) 13 (7–19·5) 0·45 12 (7–19) 13 (8–20) 0·18
SGRQ (total) 31·5 (14·9–48·2) 31·2 (16·4–47·1) 0·81 26·2 (14·0–43·6) 31·8 (17·2–47·1) 0·05
SGRQ (symptoms) 45·3 (22·9–66·3) 48·8 (27·0–66·3) 0·037 45·2 (23·5–65·1) 53·6 (34·0–69·7) 0·004
Wheezing 741 (59%) 788 (64%) 0·018 389 (60%) 116 (68%) 0·07
Data are median (IQR) or n (%). GOLD=Global Initiative for Chronic Obstructive Lung Disease. BODE=Body-mass index, airflow Obstruction, Dyspnea, and Exercise. 
COPD=chronic obstructive pulmonary disease. CAT=COPD assessment test. SGRQ=St George Respiratory Questionnaire. *Mann-Whitney rank sum test for continuous 
variables or χ² for categorical variables. †Value for all GOLD stages combined.
Table 4: Clinical characteristics for patients stratified by mean blood or sputum eosinophils
Blood eosinophils 
<200 per μL 
(n=1262)
Blood eosinophils 
≥200 per μL 
(n=1237)





Total 311 (25%) 309 (25%) 0·35 125 (19%) 44 (26%) 0·05
Requiring health-care use 294 (23%) 291 (24%) 0·36 125 (19%) 43 (25%) 0·07
Antibiotic treatment 232 (18%) 240 (19%) 0·29 92 (14%) 34 (20%) 0·09
Corticosteroid treatment 199 (16%) 209 (17%) 0·27 66 (10%) 32 (19%) 0·002
Any drug treatment 265 (21%) 273 (22%) 0·29 105 (16%) 39 (23%) 0·033
Severe† 137 (11%) 162 (13%) 0·15 52 (8%) 22 (13%) 0·044
Data are n (% positive). *χ² test. †Exacerbations involving a trip to an emergency department or admission to hospital.
Table 5: Comparison of exacerbations occurring in the previous year for patients stratified by mean blood or sputum eosinophils
QCT imaging showed that indices of emphysema 
(TLC, % voxels less than –950 HU) and air trapping 
(residual volume, % voxels less than –856 HU)24 did not 
differ between the blood eosinophil groups (table 3). By 
contrast, significantly higher emphysema indices were 
observed in the high sputum eosinophil group versus the 
low sputum eosinophil group. Additionally, air trapping 
(residual volume) and PRM for functional small airways 
disease25 were significantly higher in the high sputum 
eosinophil group than in the low sputum eosinophil 
group. A small, 0·02 mm increase in median airway wall 
thickness at the prespecified RB1 pathway in the apical 
segment of the right upper lobe (appendix pp 4–5) was 
seen in the high versus low blood eosinophil groups 
(p=0·032), but no difference was seen between the 
sputum eosinophil groups (p=0·08). Neither blood nor 
sputum stratification showed any significant difference 
in airway tapering (an index of bronchiectasis).
With the higher 300 cells per μL blood eosinophil cutoff, 
the density measures for emphysema or air trapping were 
not significantly different between groups; but the RB1 
airway wall thickness difference was less significant with 
the higher cutoff than the difference seen with the 
200 cells per μL cutoff (p=0·044 vs p=0·032). The higher 
cutoff maintained significant differences between 
low (<2%) and high (≥2%) sputum eosinophil groups in 
terms of both emphysema and air trapping indices 
(appendix p 14).
GOLD stages were significantly different between the 
high and low sputum eosinophil groups (p=0·001; table 4). 
295 (45%) of 656 patients with low sputum eosinophils 
were GOLD stage 0 versus 51 (30%) of 171 in the high 
sputum eosinophil group; and 200 (31%) of 656 were 
GOLD stage 2 in the low sputum eosinophil group versus 
76 (44%) of 171 in the high eosinophil group. No significant 
difference in GOLD stages was recorded between the low 
and high blood eosinophil groups (p=0·10). The 6­min 
walk distance, BODE index, and COPD assessment score 
were not significantly different in either blood or sputum 
eosinophil stratifications. The high blood eosinophil 
group had significantly higher proportion of patients who 
reported wheezing (788 [64%] of 1237 patients) than the 
low blood eosinophil group (741 [59%] of 1262; table 4). 
SGRQ symptom score was significantly higher in the high 
blood eosinophil group than the low blood eosinophil 
group; and both SGRQ total and symptom scores were 
significantly higher in the high sputum eosinophil group 
than the low sputum eosinophil group.
With the higher blood eosinophil cutoff of 300 cells per μL, 
a significant difference in GOLD stages was seen between 
the high and low groups (appendix p 15). With the higher 
sputum eosinophil cutoff of 2%, GOLD stages and SGRQ 
total and symptoms scores remained significantly different 
between the high and low count groups. BODE index, 
SGRQ impact, and self­reported wheezing, which were not 
significantly different with the 1·25% sputum cutoff, were 
significantly different with the 2% cutoff.
Exacerbations were compared for associations with 
blood and sputum eosinophil counts (table 5). Blood 
eosinophil counts were not significantly associated with 
any of the different categories of reported exacerbations. 
By contrast, the high sputum eosinophil group had a 
higher proportion of patients with exacerbations 
requiring corticosteroids than the low sputum eosinophil 
group (32 [19%] of 171 vs 66 [10%] of 656; p=0·002), as 
well as a higher proportion of patients with exacerbations 
requiring any drug treatment (39 [23%] of 171 vs 105 [16%] 
of 656; p=0·033) and with severe exacerbations requiring 
an emergency department visit (22 [13%] of 171 vs 52 [8%] 
of 656; p=0·044).
With the higher eosinophil cutoff of 300 cells per μL 
blood, still no significant differences were seen between 
the high and low count groups in terms of the proportions 
of patients with exacerbations; however, the 
higher 2% sputum eosinophil cutoff showed significant 
differences for all categories of COPD exacerbations 
(appendix p 16).
Tree classification analysis of the association of sputum 
and blood eosinophil counts with exacerbations selected 
sputum eosinophils before blood eosinophils, with 
similar cutoffs to those used in the sputum and blood 
eosinophil stratification (1·25% or 2% sputum 
eosinophils and 200 or 300 cells per μL blood eosinophils). 
The cutoffs were less than 1·9% or 1·9% or more for 
sputum eosinophils and less than 176 cells per μL or 
176 cells per μL or more for blood eosinophils. These 
cutoffs suggest that the 2% sputum eosinophils and 
200 cells per μL blood eosinophils investigated in our 
study were appropriate (appendix p 23). Exacerbations 
were recorded in 27 (23%) of 119 patients with sputum 
eosinophils of more than 1·9%. By contrast, 65 (9%) of 
692 patients with less than 1·9% sputum eosinophils had 
exacerbations (appendix p 23).
Figure 2: Receiver operating characteristic analysis for blood eosinophil 
prediction of sputum eosinophils
Blood eosinophils at cutoffs from 50 cells per μL (highest sensitivity) to 
500 cells per μL (lowest sensitivity) were examined for correct prediction of 
sputum eosinophils less than 1·25% or 1·25% or more. Maximum sensitivity and 
specificity were observed at a blood eosinophil cutoff of 150 cells per μL.  
















ROC analyses for blood eosinophil prediction of 
sputum eosinophils showed a weak, although significant, 
prediction of sputum eosinophils of 1·25% or more 
(AUC 0·63, p<0·0001; figure 2); ROC to predict sputum 
eosinophils of 2% or more showed similar results 
(AUC 0·64, p<0·0001; appendix p 24). The highest 
sensitivity and specificity ( shown b y Y ouden i ndex; 
appendix p 17) for predicting sputum eosinophils 
of 1·25% or more were at 150 cells per μL blood 
eosinophils; and highest sensitivity and specificity f or 
sputum eosinophils 2% or more were at 250 cells per μL 
blood eosinophils. Similar significant A UCs w ere 
observed at all the assessed adjacent cutoffs, suggesting 
that the blood eosinophil concentration above which one 
can confidently and accurately predict increased sputum 
eosinophils is not sharply defined (appendix p  1 7). 
Regardless, both associations had very large false 
discovery rates; 72% for blood eosinophils of 
150 cells per μL or more to predict sputum eosinophils 
1·25% or more (false­negative rate of 22%), and 74% for 
blood eosinophils of 250 cells per μL or more to predict 
sputum eosinophils of 2% or more (false­negative rate 
of 50%).
The correlation between sputum eosinophils and blood 
eosinophils was weak, but significant (figure 3; correlation 
coefficient r=0·178, p< 0·0001). 34 0 (4 2%) of  81 1 patients 
had discordant blood and sputum eosinophil counts; 
either high in blood or sputum counts, but not both 
simultaneously (figure 3). We compared lung function and 
reported exacerbations for patients in the two discordant 
and concordant groups (table 6). Both groups with high 
sputum eosinophils with or without high blood eosinophils 
had the lowest lung function indicators before 
bronchodilation. Lung function for the high blood plus low 
sputum eosinophils group was not significantly different 
from the group with low blood and low sputum eosinophils 
(p values not shown). The high blood plus high sputum 
eosinophil group had a greater proportion of patients with 
COPD exacerbations than the group with high blood but 
low sputum eosinophils; exacerbations treated with 
corticosteroids (p=0·006) or severe exacerbations requiring 
emergency department visit or hospital admission 
(p=0·013) were both significantly different.
Patients were stratified by previous asthma label or 
inhaled corticosteroid use and examined for interaction 
with high eosinophil counts (blood eosinophils ≥200 cells 
per μL or sputum eosinophils ≥1·25%) in terms of lung 
function and exacerbations. No significant i nteractions 
were seen (appendix pp 18–19).
Patients who did not have acceptable sputum slides 
(n=1498) were stratified by blood eosinophil counts to 
establish whether these patients had a phenotype with 
different characteristics (appendix p 20). Of these 
patients, the high eosinophil group had a slightly higher 
proportion of patients who used inhaled corticosteroids, 
had worse lung function, and had GOLD stages 3 
and 4 than the low count group, as would be expected in 
these patients who were ineligible for sputum induction, 
but otherwise resembled the larger cohort of smokers.
Another stratification examined whether the blood 
eosinophil groups showed differences when restricted to 
just the 811 patients who were also in the sputum cohort 
(appendix p 21). Compared with the whole­cohort 
proportions, the sputum cohort had slightly greater 
proportions of current smokers (low blood eosinophil 
group 47% and high group 42% in sputum subcohort vs 
low group 42% and high group 37% in whole cohort), less 
inhaled corticosteroid use (low group 26% and high group 
31% vs low group 32% and high group 38%), and slightly 
better lung function, but did not show the same radiological, 
clinical, or exacerbation differences observed for sputum 
eosinophil stratification (table 1; appendix p 21).
We examined whether the associations with worse lung 
function and quality of life, and greater exacerbations, 
emphysema, and air trapping in the high sputum 
eosinophil group were associated with increased sputum 
neutrophils as well as eosinophils. No difference in mean 
sputum neutrophil percentage between the high and low 
sputum eosinophil groups was seen (p=0·12; appendix 
p 11). Stratification of the sputum cohort into four groups 
of less than 1·25% or 1·25% or more eosinophils plus less 
than 68% or 68% or more neutrophils (on the basis of the 
mean sputum neutrophils of 68% [SD 21]), confirmed 
differences across low and high sputum eosinophil groups 
but did not show significant post­hoc differences between 
the high eosinophil plus high neutrophil and high 
eosinophil plus low neutrophil subgroups (appendix p 22).
Figure 3: Distribution of blood eosinophils with respect to sputum eosinophils
Although a significant association between blood and sputum eosinophils was seen (Pearson correlation 
coefficient r=0·178, p<0·0001), use of the cutoff of 200 cells per μL blood or more eosinophils (vertical red line) 
to predict sputum eosinophils of at least 1·25% (horizontal red line) will mistakenly identify many patients with 
lower sputum eosinophil percentages (lower right quadrant, pink) and miss many patients with actual sputum 




















This study in patients from the SPIROMICS cohort, who 
were smokers with COPD of varying severity as defined 
by GOLD stages, confirms that high concentrations of 
sputum eosinophils, but not blood eosinophils (unless in 
combination with high sputum eosinophils), identify a 
subset of patients with COPD with more severe airflow 
obstruction, worse quality of life, greater emphysema 
and air trapping, and greater number of exacerbations. 
Using sputum eosinophil stratification with cutoffs at 
either the mean (1·25%) or 2%, we found significant 
associations of high sputum eosinophil counts with 
numbers of COPD exacerbations, including those that 
are severe and those requiring corticosteroid therapy. 
Additionally, significant associations were seen between 
sputum eosinophil concentration and lung function, 
before and after bronchodilation, including increased 
bronchodilator reversibility, respiratory symptoms, 
emphysema and air trapping assessed by QCT, and 
COPD severity by GOLD stage. By contrast, blood 
eosinophils alone, with cutoffs at 200 cells per μL or 
300 cells per μL, showed no association with COPD 
exacerbations, and associations with other phenotypic 
markers were small or non­significant. Although SGRQ 
symptom scores were associated with high eosinophil 
counts in both blood and sputum, the differences 
between groups for this variable was greater with the 
sputum stratification. Furthermore, no difference in CAT 
scores was seen with either blood or sputum stratification, 
which diminishes the validity of use of this score. 
Notably, although the relationship between blood and 
sputum eosinophil counts was statistically significant, 
blood eosinophils did not reliably predict sputum 
eosinophils, showing a 72–74% false­discovery rate and a 
50% false­negative rate for sputum eosinophils of 2% or 
more. Lung function data stratified by high and low 
sputum and blood eosinophils showed no relationship 
with high blood eosinophils unless combined with high 
sputum eosinophils, whereas high sputum eosinophil 
count, regardless of blood eosinophil count, was 
associated with worse lung function. However, patients 
with COPD who had both high sputum and high blood 
eosinophil concentrations had both decreased lung 
function and more frequent exacerbations. These 
findings in a large multicentre cohort of smokers with a 
specified range of COPD severity have important 
implications for the proposed use of blood eosinophils 
alone as a predictive biomarker to guide individualised 
COPD therapies.
Our results extend observations from previous studies 
in COPD cohorts, including ECLIPSE,1 which focused 
primarily on neutrophilic airways inflammation, and, 
although reporting eosinophil presence,5 did not address 
the association of eosinophil counts with indices of 
COPD severity.4,5 The importance of our findings and of 
Th2 inflammation in COPD are emphasised by the 
recent report of Th2 gene expression overlap in airway 
epithelial samples from asthma and COPD cohorts,8 and 
by the shared clinical and biological characteristics 
between asthma and COPD that have been reported in 
Sputum <1·25% and 
blood <200 cells per μL 
(n=355)
Sputum <1·25% and 
blood ≥200 cells per μL 
(n=290)
Sputum ≥1·25% and 
blood <200 cells per μL 
(n=50)
Sputum ≥1·25% and 
blood ≥200 cells per μL 
(n=116)
p value*
Lung function before bronchodilator
FEV1 percentage predicted 77 (62–91) 74 (57–89) 62 (51–81) 66 (50–79) <0·0001
FVC percentage predicted 93 (81–101) 88 (77–100) 89 (76–99) 87 (76–96) 0·033
FEV1:FVC 0·67 (0·58–0·74) 0·66† (0·57–0·73) 0·61† (0·47–0·66) 0·61 (0·52–0·69) <0·0001
Lung function after bronchodilator
FEV1 percentage predicted 84 (70–97) 81 (66–95) 76 (63–87) 77 (63–90) 0·005
FVC percentage predicted 96 (86–106) 93 (84–104) 98 (88–104) 93 (85–104) 0·24
FEV1:FVC 0·69 (0·59–0·77) 0·67† (0·59–0·76) 0·63† (0·49–0·72) 0·64 (0·58–0·70) 0·0004
Percentage reversibility 7·8 (3·6–15·3) 8·5† (4·0–16·6) 14·5† (6·8–22·6) 11·4 (5·8–20·5) 0·0003
Exacerbations
Total exacerbations 76 (21%) 47 (16%) 10 (20%) 32 (28%) 0·07
Requiring health-care use 74 (21%) 45 (16%) 9 (18%) 31 (27%) 0·07
Antibiotics treatment 56 (16%) 36 (12%) 10 (20%) 23 (20%) 0·21
Corticosteroid treatment 37 (10%) 25 (9%) 6 (12%) 24 (21%) 0·006
Any drug treatment 61 (17%) 38 (13%) 10 (20%) 27 (23%) 0·08
Severe‡ 35 (10%) 15 (5%) 3 (6%) 17 (15%) 0·013
Data are median (IQR) or n (%). p values are for comparisons of all four groups; for variables with significant values, post-hoc pairwise comparisons (Dunn’s method) 
were done (p values not shown). *Kruskal-Wallis for continuous variables, χ² for exacerbation categories. †High sputum eosinophils plus low blood eosinophils was 
significantly different from low sputum eosinophils plus high blood eosinophils by post-hoc Dunn’s test. ‡Exacerbations involving a trip to an emergency department or 
admission to hospital.
Table 6: Lung function and exacerbations for patients in groups stratified by sputum and blood eosinophil counts
several studies.5,7,17,27,28 However, differences should be 
noted between the SPIROMICS cohort and other COPD 
cohorts. The COPDGene study29 enrolled a larger cohort 
of 10 000 patients who had an older minimum age 
(45 years) and a lower minimum smoking history 
(>10 pack­years) than the SPIROMICS cohort, but 
phenotyping with induced sputum was not done. 
Sputum was also unavailable in the Copenhagen general 
population study,20 WISDOM,21 INSPIRE, and 
TRISTAN.30 Although these studies reported 
exacerbations associated with high blood eosinophils, the 
entry requirements included past history of COPD 
exacerbations, which can affect the results because a past 
history of exacerbation is the most important factor in 
predicting future exacerbations.18
Emphasis on persistent Th2 inflammation in COPD31 
has focused on eosinophils as predictors of exacerbations. 
Bafadhel and colleagues6 reported a cluster analysis 
using blood and sputum biomarkers, and peripheral 
blood eosinophils predicted sputum eosinophil­
associated exacerbations of COPD. Sputum and 
peripheral blood eosinophils have been used to direct 
corticosteroid treatment and reduce occurrence of COPD 
exacerbations.9–11 The ECLIPSE study reported that 
1483 patients stratified by blood eosinophil counts did 
not have different numbers of COPD exacerbations in 
the previous year.5 We confirm that h igher b lood 
eosinophils are not associated with COPD exacerbations 
except when combined with increased sputum 
eosinophils or with other characteristics, such as a 
previous history of exacerbation.18 However, we 
established that in the SPIROMICS cohort, higher 
sputum eosinophil counts alone are associated with 
exacerbations even in mild to moderate COPD.
Eosinophil counts have been suggested to indicate the 
response to corticosteroids, anti­interleukin­5, or anti­
interleukin­5 receptor therapy.9–12,32 In a retrospective 
analysis of two COPD exacerbation studies with long­
acting β agonists and inhaled corticosteroids, Pascoe and 
colleagues33 showed that patients with high blood 
eosinophil counts had greater reductions in COPD 
exacerbations than those with low blood eosinophil counts. 
These observations suggest that eosinophils might be 
important in development of COPD exacerbations or as a 
potential biomarker of some COPD exacerbations. 
However, two factors might have influenced p revious 
observations that associated high blood eosinophil counts 
with greater numbers of COPD exacerbations: selection 
criteria requiring recent exacerbation and perhaps worse 
lung function are both related to future COPD 
exacerbations and might be surrogate markers of increased 
sputum eosinophils. Increased blood eosinophils, if also 
combined with increased sputum eosinophils, were 
associated with COPD exacerbations in our results in the 
SPIROMICS cohort. However, blood eosinophils alone 
were not associated with exacerbations, even when the 
patient had a previous asthma label. This observation 
contrasts with the association of blood eosinophil count of 
275 cells per μL or more with all­cause mortality in 
662 patients in a previous study;34 however, that study 
found no change after exclusion of patients with asthma.
We also examined other characteristics in the blood 
and sputum eosinophil subgroups of SPIROMICS 
patients that might suggest overlap with asthma: 
bronchodilator reversibility, IgE concentrations, and 
previous asthma label. High blood eosinophil counts 
with two different cutoffs (≥200 or ≥300 cells per μL) did 
not have greater acute bronchodilator reversibility, 
whereas increased sputum eosinophils groups did show 
significantly greater reversibility. IgE concentrations 
were significantly higher in the high versus low blood 
eosinophil groups, but no difference was seen between 
the sputum groups. However, the IgE concentrations in 
the SPIROMICS blood and sputum eosinophil 
subgroups were well below the median (91 IU per mL) 
and high (173 IU per mL) IgE cutoffs reported in a study 
of asthma–COPD overlap syndrome.35 Only grouping 
by 2% or more sputum eosinophils showed differences 
in proportions of patients who reported previous asthma 
label; but the proportion reporting asthma was still small 
(12·5% of the ≥2% group).
A higher proportion of patients had been prescribed 
inhaled corticosteroids in the high blood and sputum 
eosinophil groups than in the low eosinophil groups. 
This observation was made despite an expected reduction 
in eosinophil concentrations with corticosteroid therapy. 
Use of corticosteroids in the higher eosinophil groups 
potentially reflects individuals who are more likely to 
have had exacerbations, consistent with GOLD guideline 
recommendations for corticosteroids in patients with 
COPD who have frequent exacerbations.13
Limitations of this report include somewhat milder 
COPD in the group who were able to successfully induce 
sputum. For safety reasons, SPIROMICS patients with 
post­bronchodilator FEV1 percentage predicted less than 
35% did not have sputum induction, limiting the sputum 
subgroup to patients with GOLD stages 0–3. Although our 
cohorts (both for blood and sputum eosinophil analyses) 
included patients who smoked and had at least 20 pack­
years but had GOLD stage 0 (ie, had preserved lung 
function so did not meet the criteria for COPD diagnosis), 
these patients were included because they have been 
shown to have symptoms, exacerbations, activity 
limitations, and radiological evidence of airway disease 
consistent with early COPD.36 Although SPIROMICS 
exacerbations data were retrospective, validity of 
retrospective data for future risk of COPD exacerbation 
has been shown in the ECLIPSE study, in which self­
reported exacerbations from the previous year had 
predicted exacerbations during the first year of follow­up 
more accurately than all other variables examined.18 An 
additional limitation, at least in clinical settings, is the 
difficulty of accurate sputum analysis. Even in the 
SPIROMICS network with centralised training for 
sputum induction and processing, some factors still 
prevented sputum analysis on all eligible patients 
(appendix pp 2–5). However, analysis of those who did not 
have sputum analysis stratified by blood eosinophil 
concentrations did not differ substantially from the larger 
cohort who did have sputum samples taken.
Of interest, longitudinal follow­up of the SPIROMICS 
cohort might be used to confirm the observations of 
Hospers and colleagues,34 that peripheral eosinophils are 
associated with all­cause mortality over a period of 
30 years. Alternatively, the differences in lung function 
associated with blood eosinophil counts (cutoff 2%) 
observed in the much smaller study over 9 years by 
Rogliani and colleagues37 should be examined in the 
larger SPIROMICS cohort longitudinally.
In summary, using the large and comprehensive 
phenotypic characterisation of the SPIROMICS cohort, 
we show that stratification by increased sputum 
eosinophil inflammation identified a subgroup with 
more severe COPD, decreased lung function, worse 
emphysema and air trapping, and more COPD 
exacerbations. Peripheral blood eosinophil counts 
identified a subgroup with decreased lung function 
without other indices of more severe COPD, specifically 
exacerbations, unless examined on the background of 
increased sputum eosinophils. Furthermore, blood 
eosinophil counts did not accurately predict sputum 
eosinophil counts. These observations confirm the 
importance of assessing eosinophils in the airways. In 
future, patients with high sputum eosinophil 
concentrations should be followed longitudinally to 
establish whether this factor has long­term effects on the 
progression of COPD.
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